Mannucci PM, Tuddenham EG (2001) The hemophilias–from Royal genes to gene therapy. N Engl J Med 344(23):1773–1779

Article  CAS  PubMed  Google Scholar 

Franchini M, Mannucci PM (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7:24

Article  PubMed  PubMed Central  Google Scholar 

Bolton-Maggs PH, Pasi KJ (2003) Haemophilias A and B. Lancet 361(9371):1801–1809

Article  CAS  PubMed  Google Scholar 

Dimichele D (2002) Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 8(3):280–287

Article  CAS  PubMed  Google Scholar 

DiMichele D (2007) Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 138(3):305–315

Article  CAS  PubMed  Google Scholar 

Eckhardt CL, Van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G et al (2013) Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 122(11):1954–1962

Article  CAS  PubMed  Google Scholar 

Lindvall K, von Mackensen S, Elmståhl S, Khair K, Stain AM, Ljung R, Berntorp E (2014) Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer 61(4):706–711

Article  PubMed  Google Scholar 

Guh S, Grosse S, McAlister S, Kessler C, Soucie J (2012) Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 18(2):268–275

Article  CAS  PubMed  Google Scholar 

Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T et al (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339(8793):594–598

Article  CAS  PubMed  Google Scholar 

Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A et al (1995) Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 74(6):1402–1406

Article  CAS  PubMed  Google Scholar 

Goodeve AC, Williams I, Bray GL, Peake IR (2000) Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with Recombinant factor VIII (Recombinate). Recombinate PUP study group. Thromb Haemost 83(6):844–848

Article  CAS  PubMed  Google Scholar 

Thorland E, Drost J, Lusher J, Warrier I, Shapiro A, Koerper M et al (1999) Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 5(2):101–105

Article  CAS  PubMed  Google Scholar 

Batsuli G, Deng W, Healey JF, Parker ET, Baldwin WH, Cox C et al (2016) High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. Blood 128(16):2055–2067

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minno GD, Santagostino E, Pratt K, Königs C (2014) New predictive approaches for ITI treatment. Haemophilia 20(Suppl 6):27–43

Article  CAS  PubMed  Google Scholar 

Ibrahim UA, Ahmed SG (2018) Determinants and modifiers of bleeding phenotypes in haemophilia-A: general and tropical perspectives. Egypt J Med Hum Genet 19(3):171–178

Article  Google Scholar 

Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS (1985) Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A 82(22):7728–7732

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A et al (2002) The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 346(9):662–667

Article  CAS  PubMed  Google Scholar 

Ghosh K, Shetty S (2009) Immune response to FVIII in hemophilia A: an overview of risk factors. Clin Rev Allergy Immunol 37:58–66

Article  CAS  PubMed  Google Scholar 

Soucie JM, Evatt B, Jackson D, Investigators HSSP (1998) Occurrence of hemophilia in the United States. Am J Hematol 59(4):288–294

Article  CAS  PubMed  Google Scholar 

Key NS (2004) Inhibitors in congenital coagulation disorders. Br J Haematol 127(4):379–391

Article  CAS  PubMed  Google Scholar 

Qu H-Q, Fisher-Hoch SP, McCormick JB (2011) Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases. Int J Infect Dis 15(5):e305–e13

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark DP, Pazdernik NJ (2013) Chapter 23 - Mutations and repair. In: Clark DP, Pazdernik NJ (eds) Molecular biology (Second Edition). Academic, Boston, pp 721–766

Google Scholar 

Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD et al (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312(5992):342–347

Article  CAS  PubMed  Google Scholar 

Scandella D, Mattingly M, de Graaf S, Fulcher CA (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. https://doi.org/10.1182/blood.V74.5.1618.1618

Article  PubMed  Google Scholar 

Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW (1992) A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 67(06):665–671

Article  CAS  PubMed  Google Scholar 

Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M et al (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. https://doi.org/10.1182/blood.V86.5.1811.bloodjournal8651811

Article  PubMed  Google Scholar 

Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P (1995) Residues 484–508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270(24):14505–14509

Article  CAS  PubMed  Google Scholar 

Fakharzadeh SS, Kazazian HH Jr (2000) Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26(2):167–171

Article  CAS  PubMed  Google Scholar 

Iioka F, Shimomura D, Nakamura F, Ohno H, Yada K, Nogami K, Shima M (2014) Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor. Haemophilia 20(6):e402–e404

Article  CAS  PubMed  PubMed Central  Google Scholar 

AWIDI A, RAMAHI M, AlHATTAB D, MEFLEH R, DWEIRI M, BSOUL N et al (2010) Study of mutations in Jordanian patients with haemophilia A: identification of five novel mutations. Haemophilia 16(1):136–142

Article  CAS  PubMed  Google Scholar 

Goodeve AC, Williams I, Bray GL, Peake IR, Group RPS (2000) Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with Recombinant factor VIII (Recombinate™). Thromb Haemost 83(06):844–848

Article  CAS  PubMed